La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cabaletta Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cabaletta Bio..

Cabaletta Bio (NASDAQ:CABA) Azioni, Catena delle Opzioni

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Cabaletta Bio Inc

Cabana Target Beta ETF

Cabana Target Drawdown 10 ETF

Cabana Target Leading Sector Moderate ETF

WIIM

Suburban Propane Partners shares are trading lower after the company reported worse-than-expected Q4 financial results.

Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) reported quarterly earnings of $0.07 per share. This is a 177.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported $8.84 million in sales this quarter. This is a 126.76 percent increase over sales of $3.90 million the same period last year.

Earnings

News

SRTS

Sensus Healthcare Q3 EPS $0.07 Up From $(0.09) YoY, Sales $8.84M Up From $3.90M YoY

RBC Capital analyst Gregory Renza maintains Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) with a Outperform and lowers the price target from $4 to $2.

Price Target

Analyst Ratings

VIRX

RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $2

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: Disney Surges On Strong Q4 Results, S&P Falls Slightly, PPI Figures Fall Relatively In Line With Estimates

Craig-Hallum analyst George Sutton maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $15 to $32.

Craig-Hallum Maintains Buy on Hut 8, Raises Price Target to $32

SPIR

Spire Global shares are trading higher after Craig-Hallum upgraded the stock from Hold to Buy and raised its price target from $8 to $20. Also, Baird raised its price target from $9 to $16.

PDSB

PDS Biotechnology shares are trading lower after the company reported worse-than-expected Q3 financial results.

<a href="https://www.barrons.com/articles/citigroups-probe-russian-oligarch-kerimov-c10cfa2e">https://www.barrons.com/articles/citigroups-probe-russian-oligarch-kerimov-c10cfa2e</a>
<a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">Citigroup</a> is being investigated by several U.S. agencies for the work it has done for a trust that holds the assets of Suleiman Abusaidovich Kerimov, a Russian official sanctioned by the U.S. government, as federal officials continue to scrutinize how Russia's oligarchs store and access their assets abroad.
The Department of Justice, the Federal Bureau of Investigation, and the Internal Revenue Service have been investigating the matter for more than a year, a person with knowledge of the situation said.
The probe centers on <a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">Citigroup</a>
<a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">C</a>
<a href="https://www.barrons.com/market-data/stocks/c?mod=article_chiclet">-0.91%</a>
providing services to Heritage Trust, which held the assets of <a href="https://www.wsj.com/articles/u-s-targets-russian-oligarchs-in-new-sanctions-1523018826?mod=article_inline">Kerimov</a>, an ally of Russian President Vladimir Putin who made his fortune in the Russian gold mining industry. The U.S. government has <a href="https://home.treasury.gov/news/press-releases/jy0841">said</a> the trust was formed seven years ago to hold and manage Kerimov's U.S.-based assets.
&nbsp;
The probe also focuses on Citi's financial compliance framework, such as the anti-money-laundering and client-vetting processes designed to prevent financial crimes. While Citi's trust business still has the Heritage Trust account on its books, the bank cannot administer it as a typical trust—by distributing or accepting funds—while it is blocked by the Treasury Department.
"Citi is committed to conducting all business with the highest consideration for compliance with all applicable laws and regulations," the Citi spokesperson said in a statement to Barron's. "At the same time, we are actively ending nearly all of our institutional banking business in Russia, except for those operations necessary to fulfill remaining legal and regulatory obligations, while we proceed with the closing of our Russian consumer banking business."
Kerimov and his representatives were unable to be reached by Barron's. The Justice Department declined to comment. The IRS and FBI didn't provide comment. Clifford Chance, the law firm Citi hired as outside counsel, declined to comment.
Kerimov is the world's 293rd-richest person, according to the 500-person <a href="https://www.bloomberg.com/billionaires/profiles/suleiman-a-kerimov/">Bloomberg Billionaires Index</a>, with a net worth of nearly $10 billion. The U.S. said it <a href="https://home.treasury.gov/news/press-releases/sm0338">imposed sanctions</a> on Kerimov in 2018 for being an official of the Government of the Russian Federation. Kerimov was also sanctioned by the European Union, Japan, and other countries.
Two years ago the Treasury Department <a href="https://home.treasury.gov/news/press-releases/jy0841">blocked</a> Kerimov from accessing Heritage Trust, which held $1 billion as of June 2022, as part of an investigation into the oligarch's "use of a network of relatives, advisors, and opaque legal entities to invest in the United States." That year, the Justice Department ordered the <a href="https://www.justice.gov/opa/pr/300-million-yacht-sanctioned-russian-oligarch-suleiman-kerimov-seized-fiji-request-united">seizure</a> of a superyacht that it alleged was owned by Kerimov and subject to forfeiture over probable cause of U.S. law violations, including money laundering and conspiracy.
Citi offers trust and wealth planning services to rich clients through its private bank, which is part of the wealth management division. The bank is in the process of <a href="https://www.barrons.com/articles/citigroup-sale-trust-unit-jtc-0bbf04e1?mod=article_inline">selling its trust unit</a> to JTC, a firm based on the English Channel island of Jersey that has expanded in the U.S. through acquisitions, for $80 million. Citi's wealth arm manages $580 billion of investment assets. JTC declined to comment.
Citi is facing federal scrutiny over issues with its internal controls. The Office of the Comptroller of the Currency and the Federal Reserve <a href="https://www.barrons.com/articles/bank-regulators-fine-citi-e3b08ee6?mod=article_inline">fined Citi in July</a> after the regulators found the bank hadn't made enough progress in remedying four-year-old consent orders tied to insufficient risk management oversight.
Chief Executive Officer Jane Fraser said in July that "despite making good progress in simplifying our firm" and addressing the consent orders, "there are areas where we have not made progress quickly enough, such as in our data quality management." The bank has "intensified our focus and increased our investment in those areas over the last several months," she said.
Under Fraser, who has led the fourth-largest U.S. lender since March 2021, Citi is aiming to engineer a turnaround after years of problems with financial regulators, poor returns, and high-profile missteps.
Until the Treasury Department prevented Kerimov from accessing Heritage Trust in 2022, Kerimov used "a complex series of legal structures to continue to retain an interest in, and benefit from, his over $1 billion in assets in the United States," said Andrea Gacki, director of the Treasury's Financial Crimes Enforcement bureau, in a <a href="https://www.fincen.gov/news/speeches/prepared-remarks-fincen-director-andrea-gacki-during-beneficial-ownership-1">speech</a> this past August.
"These funds were invested in large public and private U.S. companies and managed by a series of U.S. investment firms and facilitators," Gacki said. "Along the way, Kerimov and his proxies used various layers of shell companies, including [limited liability companies], to conceal his interest."
The probe of the bank and Kerimov comes as the U.S. government continues to <a href="https://www.wsj.com/articles/prosecutors-targeting-russian-oligarchs-shift-focus-to-service-providers-that-support-them-11669767556?mod=article_inline">investigate the ecosystem of service providers</a>, including financial firms, that the government alleges enable Russian oligarchs to move their money and evade sanctions. In March 2022, following Russia's invasion of Ukraine, the Justice Department formed a task force with other U.S. agencies, including the FBI and the IRS, to enforce sanctions and take action against Russian oligarchs.

Global

'Citigroup's Ties To Russian Oligarch Kerimov Draw Federal Scrutiny' - Barron's

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and raises the price target from $72 to $80.

INCY

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $80

Turning Point Brands shares are trading higher after the company announced a joint venture with the Tucker Carlson Network. Also, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $65.

Craig-Hallum analyst Greg Palm maintains Stratasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) with a Buy and raises the price target from $12 to $15.

SSYS

Craig-Hallum Maintains Buy on Stratasys, Raises Price Target to $15

Trading Ideas

GORV

Lazydays Holdings Shares Resume Trade Then Again Halt On Circuit Breaker To The Downside, Stock Now up 70.7%

RBC Capital analyst Ken Herbert reiterates Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) with a Outperform and maintains $100 price target.

Reiteration

LOAR

RBC Capital Reiterates Outperform on Loar Holdings, Maintains $100 Price Target

APEI

American Public Education shares are trading lower. Truist Securities maintained a Hold rating on the stock.

RBC Capital analyst Daniel Perlin reiterates Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Outperform and maintains $572 price target.

RBC Capital Reiterates Outperform on Mastercard, Maintains $572 Price Target

DTST

Data Storage shares are trading lower after the company reported worse-than-expected Q3 financial results.

B of A Securities analyst Peter Henderson maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $125 to $149.

B of A Securities Maintains Buy on Live Nation Entertainment, Raises Price Target to $149

Joe Moglia, former CEO of TD Ameritrade, on Thursday asserted that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is a permanent fixture in the financial landscape, with substantial <a href="https://www.benzinga.com/money/bitcoin-price-prediction">growth prospects ahead</a>.
What Happened: Speaking with CNBC, Moglia <a href="https://www.cnbc.com/video/2024/11/13/fmr-td-ameritrade-ceo-joe-moglia-bitcoin-is-here-to-stay-will-have-significant-growth-ahead-of-it.html">emphasized </a>that while several years ago the concept of cryptocurrency was widely dismissed by traditional finance, the current sentiment reflects a remarkable shift.
"Bitcoin is legitimately here to stay," Moglia said. &#8220;I think it's going to have significant growth ahead of it.&#8221;
Moglia also highlighted the pro-business stance expected from the new administration, which he believes will foster a friendlier environment for the cryptocurrency industry.
He pointed out that the regulatory shift <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">under Trump's administration</a>, along with recent moves by prominent Wall Street institutions, signals that Bitcoin's role in finance is solidifying.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41973094/elon-musk-says-excess-government-spending-causes-inflation-as-donald-trump-fills-administration-with-cryptocurrency-advocates">Elon Musk Says Excess Government Spending &#8216;Causes Inflation&#8217; As Donald Trump Fills Administration With Cryptocurrency Advocates</a>
"Trump wasn't a big fan of Bitcoin before," Moglia noted, "but now he's Mr. Bitcoin," referring to Trump's stance on creating a U.S. strategic Bitcoin reserve and fostering cryptocurrency innovation.
The recent turn of events under the Trump administration, with plans to lower taxes and deregulate sectors such as finance and cryptocurrency, is seen as a &#8220;home run&#8221; for Bitcoin and other major digital assets like Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). 
The former TD Ameritrade CEO said that shifting views, even among critics such as <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40828224/jpmorgan-ceo-jamie-dimon-said-hed-fire-in-a-second-anyone-caught-trading-bitcoin-when-it-w">JPMorgan's Jamie Dimon</a>, underscore the growing acceptance of cryptocurrencies in mainstream finance.
Moglia's optimistic outlook aligns with the anticipated discussions at the upcoming Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry leaders will explore the latest trends, regulatory developments, and investment opportunities in the evolving crypto market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41969740/bitcoin-stays-above-91000-but-one-technical-indicator-spells-trouble">Bitcoin Stays Above $91,000—But One Technical Indicator Spells Trouble</a></li>
</ul>
Image: Pexels

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

'Bitcoin Is Here To Stay, Poised For Significant Growth,' Says Former TD Ameritrade CEO Joe Moglia

BSGM

BioSig Technologies shares are trading higher after the company announced it regained Nasdaq compliance status regarding its minimum bid price rule.

B of A Securities analyst Mihir Bhatia maintains Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) with a Underperform and raises the price target from $14 to $15.

B of A Securities Maintains Underperform on Rocket Companies, Raises Price Target to $15

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential

Warning: CABA is at high risk of performing badly

Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital +

Cabaletta Bio GAAP EPS of -$0.62 misses by $0.03

TD Cowen analyst Phil Nadeau has maintained their bullish stance on CABA stock, giving a Buy rating on November 5. Phil Nadeau has given his Buy ra...

Cabaletta Bio's Promising Trial Results and Proactive Management Secure Buy Rating

ARLP

ASPI

CABA

CRMD

DUKB

KYTX

MSTLW

MVIS

NBIS

SKYX

SOJC

SOJD

SOJE

SPGYF

Press Releases

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Comments

Cabaletta Bio

Cabaletta Bio (CABA) Opzioni

Cabaletta Bio (NASDAQ:CABA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO